Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 50, 2009, Pages 21282-21287

  Yazinski, Stephanie A ^a   Westcott, Peter M K ^a   Ong, Kelly ^a   Pinkas, Jan ^b,c   Peters, Rachel M ^a   Weiss, Robert S ^a  

^a Cornell University ^*  (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c IMMUNOGEN INC   (United States)

Author keywords

Breast cancer; DNA damage checkpoint

Indexed keywords

PROTEIN; PROTEIN P53; PROTIEN HUS1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CANCER INHIBITION; CELL DAMAGE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ECTOPIC BREAST; FEMALE; HOMEOSTASIS; MAMMARY GLAND; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; TISSUE REGENERATION;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; EPITHELIUM; FEMALE; HOMEOSTASIS; MAMMARY GLANDS, ANIMAL; MICE; MICE, KNOCKOUT; REGENERATION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 75849137153     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0904965106     Document Type: Article

References (49)

1. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366-374.
2. Bartek J, Lukas J (2007) DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol 19:238-245.
3. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103-105.
4. Soussi T (2007) p53 alterations in human cancer: More questions than answers. Oncogene 26:2145-2156.
5. Rodier F, Campisi J, Bhaumik D (2007) Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 35:7475-7484.
6. Maier B, et al. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306-319.
7. Tyner SD, et al. (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415:45-53.
8. Valentin-Vega YA, Okano H, Lozano G (2008) The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ 15:1772-1781.
9. Matheu A, et al. (2007) Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448:375-379.
10. Wells BS, Yoshida E, Johnston LA (2006) Compensatory proliferation in Drosophila imaginal discs requires Dronc-dependent p53 activity. Curr Biol 16:1606-1615.
11. Bartek J, Bartkova J, Lukas J (2007) DNA damage signaling guards against activated oncogenes and tumor progression. Oncogene 26:7773-7779.
12. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B (2002) Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 62:4095-4099.
13. Menoyo A, et al. (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 61:7727-7730.
14. Bertoni F, et al. (1999) CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26:176-180.
15. de la Torre J, et al. (2008) Expression of DNA damage checkpoint protein Hus1 in epithelial ovarian tumors correlates with prognostic markers. Int J Gynecol Pathol 27:24-32.
16. Zhu A, Zhang CX, Lieberman HB (2008) Rad9 has a functional role in human prostate carcinogenesis. Cancer Res 68:1267-1274.
17. Verlinden L, et al. (2007) The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 67:6574-6581.
18. Cheng CK, Chow LW, Loo WT, Chan TK, Chan V (2005) The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 65:8646-8654.
19. Maniwa Y, et al. (2005) Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells. Cancer 103:126-132.
20. Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14:397-402.
21. Lam MH, Liu Q, Elledge SJ, Rosen JM (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6:45-59.
22. Liu Q, et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459.
23. Parrilla-Castellar ER, Arlander SJ, Karnitz L (2004) Dial 9-1-1 for DNA damage: The Rad9-Hus1-Rad1 (9 -1-1) clamp complex. DNA Repair 3:1009-1014.
24. Burrows AE, Elledge SJ (2008) How ATR turns on: TopBP1 goes on ATRIP with ATR. Genes Dev 22:1416-1421.
25. Weiss RS, Enoch T, Leder P (2000) Inactivation of mouse Hus1 results in genomic instability and impaired responses to genotoxic stress. Genes Dev 14:1886-1898.
26. Hopkins KM, et al. (2004) Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol 24:7235-7248.
27. Levitt PS, Liu H, Manning C, Weiss RS (2005) Conditional inactivation of the mouse Hus1 cell cycle checkpoint gene. Genomics 86:212-224.
28. Selbert S, et al. (1998) Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res 7:387-396.
29. + cell cycle checkpoint gene. Genomics 59:32-39.
30. Silberstein GB (2001) Postnatal mammary gland morphogenesis. Microsc Res Tech 52:155-162.
31. Heatwole VM (1999) TUNEL assay for apoptotic cells. Methods Mol Biol 115:141-148.
32. Scholzen T, Gerdes J (2000) The Ki-67 protein: From the known and the unknown. J Cell Physiol 182:311-322.
33. Vidanes GM, Bonilla CY, Toczyski DP (2005) Complicated tails: Histone modifications and the DNA damage response. Cell 121:973-976.
34. Zhu M, Weiss RS (2007) Increased common fragile site expression, cell proliferation defects, and apoptosis following conditional inactivation of mouse Hus1 in primary cultured cells. Mol Biol Cell 18:1044-1055.
35. Weiss RS, Matsuoka S, Elledge SJ, Leder P (2002) Hus1 acts upstream of chk1 in a mammalian DNA damage response pathway. Curr Biol 12:73-77.
36. Jerry DJ, et al. (1998) Delayed involution of themammaryepithelium in BALB/c-p53null mice. Oncogene 17:2305-2312.
37. Zaugg K, et al. (2007) Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci USA 104:3805-3810.
38. Ruzankina Y, et al. (2007) Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1:113-126.
39. Levitt PS, et al. (2007) Genome maintenance defects in cultured cells and mice following partial inactivation of the essential cell cycle checkpoint gene Hus1. Mol Cell Biol 27:2189-2201.
40. Vandivier RW, Henson PM, Douglas IS (2006) Burying the dead: The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129:1673-1682.
41. Fan Y, Bergmann A (2008) Distinct mechanisms of apoptosis-induced compensatory proliferation in proliferating and differentiating tissues in the Drosophila eye. Dev Cell 14:399-410.
42. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516-521.
43. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M (2009) ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 5:e1000324.
44. Sidi S, et al. (2008) Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133:864-877.
45. Greenow KR, Clarke AR, Jones RH (2009) Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28:1443-1453.
46. Zhang M, et al. (2008) Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 68:4674-4682.
47. Ashwell S, Zabludoff S (2008) DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14:4032-4037.
48. Chen Z, et al. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119:2784-2794.
49. Coppe JP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853-2868.